Crossless retroviral vectors
    1.
    发明授权
    Crossless retroviral vectors 有权
    无反转录病毒载体

    公开(公告)号:US06333195B1

    公开(公告)日:2001-12-25

    申请号:US09479776

    申请日:2000-01-07

    IPC分类号: C12N15867

    摘要: Retroviral vector constructs are described which have a 5′ LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3′ LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.

    摘要翻译: 描述了具有5'LTR,tRNA结合位点,包装信号,一个或多个异源序列,第二链合成起始和3'LTR的逆转录病毒载体构建体,其中载体构建体缺乏逆转录病毒gag / pol或env 编码序列。 此外,描述了gag / pol和env表达盒,其中表达盒缺少共同超过8个核苷酸的连续序列。 上述逆转录病毒载体构建体,gag / pol和env表达盒可用于构建排除形成复制能力的病毒的生产细胞系。

    Crossless retroviral vectors
    2.
    发明授权
    Crossless retroviral vectors 失效
    无反转录病毒载体

    公开(公告)号:US6013517A

    公开(公告)日:2000-01-11

    申请号:US850961

    申请日:1997-05-05

    摘要: Retroviral vector constructs are described which have a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3' LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression-cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.

    摘要翻译: 描述了具有5'LTR,tRNA结合位点,包装信号,一个或多个异源序列,第二链合成起始和3'LTR的逆转录病毒载体构建体,其中该载体构建体缺乏逆转录病毒gag / pol或env 编码序列。 此外,描述了gag / pol和env表达盒,其中表达盒缺少多于8个核苷酸的连续序列。 上述逆转录病毒载体构建体,gag / pol和env表达盒可用于构建排除形成复制能力的病毒的生产细胞系。

    Retroviral delivery of full length factor VIII
    3.
    发明授权
    Retroviral delivery of full length factor VIII 失效
    逆转录病毒递送全长因子VIII

    公开(公告)号:US5681746A

    公开(公告)日:1997-10-28

    申请号:US366851

    申请日:1994-12-30

    摘要: Retroviral vectors for directing expression of full length factor VIII in transduced host cells, plasmids encoding the same, and host cells transformed, transfected, or transduced therewith are disclosed. Also disclosed are retroviral particles comprising such retrovital vectors, as are methods for making such particles in suitable packaging cells. Retroviral particles so produced may be amphotropic, ecotropic, polytropic, or xenotropic; alternatively, they may comprise chimeric or hybrid envelope proteins to alter host range. Also described are retrovital particles comprising retroviral vectors for directing full length factor VIII expression which are complement resistant. Pharmaceutical compositions comprising retrovital particles of the invention are also disclosed, as are methods of treating mammals, particularly humans, afflicted with hemophilia.

    摘要翻译: 公开了用于在转导的宿主细胞中指导全长因子VIII表达的逆转录病毒载体,编码它们的质粒和转化,转染或转导的宿主细胞。 还公开了包含这种逆转录病毒载体的逆转录病毒颗粒,以及在合适的包装细胞中制备这种颗粒的方法。 如此产生的逆转录病毒颗粒可以是单调性,亲和性,多变性或异位性; 或者,它们可以包含嵌合或杂合包膜蛋白以改变宿主范围。 还描述了包含用于引导补体抗性的全长因子VIII表达的逆转录病毒载体的逆转颗粒。 还公开了包含本发明的逆转录病毒颗粒的药物组合物,以及治疗患有血友病的哺乳动物,特别是人的方法。

    Anti-cancer immunotherapeutics
    6.
    发明授权
    Anti-cancer immunotherapeutics 失效
    抗癌免疫治疗

    公开(公告)号:US5693522A

    公开(公告)日:1997-12-02

    申请号:US371922

    申请日:1995-01-11

    摘要: The present invention provides a method of destroying selected tumor cells comprising administering to a warm-blooded animal a vector construct which directs the expression of at least one immunogenic, non-tumorigenic form of an altered cellular component normally associated with the selected tumor cells. Also provided are vector constructs which direct the expression of altered cellular components. Representative altered cellular components include ras.sup.*, p53.sup.*, Rb.sup.*, alter protein encoded by the Wilms' tumor gene, ubiquitin.sup.*, mucin.sup.*, DCC, APC, MCC, neu, an altered receptor, and bcr/abl. Also provided are recombinant viruses carrying a vector construct, target cells infected with the recombinant virus, and pharmaceutical compositions comprising the recombinant virus and a pharmaceutically acceptable carrier or diluent.

    摘要翻译: 本发明提供了破坏所选择的肿瘤细胞的方法,包括向温血动物施用指导至少一种免疫原性,非致瘤性形式的通常与所选择的肿瘤细胞相关的改变的细胞组分的载体构建体。 还提供了引导改变的细胞组分的表达的载体构建体。 代表性改变的细胞成分包括由Wilms肿瘤基因编码的ras *,p53 *,Rb *,改变的蛋白质,泛素*,粘蛋白*,DCC,APC,MCC,neu,改变的受体和bcr / abl。 还提供携带载体构建体的重组病毒,用重组病毒感染的靶细胞,以及包含重组病毒和药学上可接受的载体或稀释剂的药物组合物。